Based on these data, the authors proposed that DPP3 overexpression promotes breast cancer progression, metastasis and drug resistance, stabilizing NRF2, while the signature characterized by high levels of NRF2 and DPP3 might represent a potential biomarker for breast cancer prognosis and treatment. This evidence concerns the gene DPP3 and breast cancer.